And to make sure the company’s mRNA product list continues to flourish worldwide, Moderna announced its Global Public Health Strategy and mRNA Access program on March 7, 2022. Noting that the COVID-19 pandemic “will not be our last,” mRNA Access invites researchers worldwide to partner with Moderna to “explore the possibility of mRNA for the benefit of global health.”
Armed with “equity awareness” and the fear of the next pandemic, the strategy commits Moderna to “advance vaccines targeting 15 pathogens identified as [the] biggest public health risk by WHO and CEPI into clinical studies by 2025.”
“There is a way that seems right to a man, But its end is the way of death.” Proverbs 19:12
Bancel’s blunt forewarning of mRNA’s global invasion should shock no one. Despite a looming snag with Pfizer over its mRNA technology platform, Moderna has spent years preparing for this moment. Last month, along with global partnerships focused on expanding mRNA technology in Belgium, Denmark, the Netherlands, Norway, Poland, Sweden, and Canada, Moderna cemented a 10-year partnership with the U.K. government. Likewise, the company is actively talking with China about supplying the country with its mRNA products.
Indeed, mRNA is not going away. Instead, it is the holy grail of the global elite, opening the door to implementing technology to overcome sickness. Some call that a giant step towards transhumanism. For Moderna, its one-sentence mission statement conveys the company’s explicit, full-speed-ahead international goal: “Our mission is to deliver the greatest possible impact to people through mRNA medicines.”
Read More @ The Highwire HERE
